Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page
- Check2 days agoChange DetectedThe old and new screenshots show the same Record History content with only minor visual/layout adjustments; no data, version entries, or study details appear to have changed.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check30 days agoChange Detected- Added a government funding lapse notice with operating status guidance and a link to cc.nih.gov and opm.gov. - Updated version from v3.1.0 to v3.2.0.SummaryDifference9%

- Check38 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.2%

- Check52 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed.SummaryDifference0.5%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.5%

- Check66 days agoChange DetectedThe web page has added a facility name and location details, while removing specific state, country, and city information. This indicates a shift towards a more generalized presentation of location data.SummaryDifference54%

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.